Alterations in oncogenes are critical steps in the development of endometrial cancer. To investigate the potential clinical relevance of the amplification of the oncogenes c-erbB2, c-myc, and int-2 and the mutation of K-ras in endometrial cancer, 112 tumors were examined using PCR-based fluorescent DNA technology. Amplification of the three oncogenes and the mutation of K-ras were correlated with age, tumor size, lymph node status, metastases, stage, histological types, grade, steroid hormone receptor expression (estrogen receptor, ER; progesterone receptor, PgR), family history of cancer, previous history of cancer or precursor lesions, and previous history of hormone replacement therapy. Oncogene amplification of c-erbB2 was detected in 18.9%, of c-myc in 2.7% and of int-2 in 4.2%, and K-ras mutation in 11.6%. No significant correlations could be detected between amplification of c-erbB2 and any of the other parameters. Mutation of K-ras is associated with positive expression of PgR. This might indicate that mutation and activation of K-ras are involved in the development of hormonal independence in endometrial cancer.
Introduction
Endometrial cancer is the most abundant female genital cancer with a significant increase in the cause-specific death rate over the last few years, which may reflect the aging population [1, 2] . According to the FIGO classification (1988), the staging of endometrial cancer is based upon surgical findings. The three major criteria for therapeutic decisions include myometrial invasion, tumor grading, and extrauterine tumor spread [3, 4] . The search for prognostic and/or predictive factors in endometrial cancer include DNA ploidy and S-phase [5, 6] , expression of the steroid hormone receptors [7] [8] [9] , the epidermal growth factor receptor, the Her-2/neu protein, and the p53 protein [10] [11] [12] [13] [14] [15] . In these studies tumors with high FIGO classification showed decreased estrogen (ER) and progesterone receptor (PgR) expression [7, 8] and increased epidermal growth factor receptor, Her-2/neu, and p53 expression [6, [11] [12] [13] [14] [15] . By univariant or multivariant analyses, none of these parameters proved to be more relevant than the three major prognostic parameters. Genetic alterations in the development of endometrial carcinomas have not been well characterized, little is known about oncogene and tumor suppressor gene activity in these carcinomas. Cytogenetic and molecular genetic analyses of endometrial cancer samples have found amplification of the c-erbB2 gene [10, 11] , mutations in the p53 gene [14, 15] , microsatellite instability and mutation in the K-ras gene [16] [17] [18] [19] , deletion in the DCC gene [20] , and loss of heterozygosity at chromosomes 1p, 3p, 8p, 9p, 10q, 14q, 16q, 17q, and 18q [21] [22] [23] [24] . The main focus of these studies was directed towards their relevance for tumor development and their role in the multistep carcinogenesis of endometrial cancer. They encompass a small number of cases and do not focus on prognostic values or correlations with histological or clinical parameters.
Gene amplification is a common mechanism of protooncogene activation and is believed to play a key role in neoplastic cell transformation and tumor progression. Mutations in oncogenes are a rare phenomenon. In this retrospective study, a rapid, non-radioactive, highly sensitive approach based on differential PCR and fluorescent DNA technology for quantitative determination of oncogene amplification in formalin-fixed, paraffin-embedded endometrial carcinomas was established. Furthermore, a fluorescence-based sequencing strategy was used for confirmation of single-strand conformation polymorphism (SSCP) screened alterations in the K-ras oncogene.
Materials and Methods
Patient Characteristics, Surgical Procedures, and Adjuvant Therapy. The study included 112 patients who were treated for primary endometrial cancer at the Department of Obstetrics and Gynecology, Heinrich-Heine-University, Düsseldorf, from January 1980 to December 1994 and from whom complete follow-up data were available. An abdominal hysterectomy and bilateral oophorectomy were performed in all patients. In 75 patients with advanced stage or palpable lymph nodes, lymphadenectomy was performed by removing the lymphatic tissue along the external and internal iliac veins and arteries, and in the obturator fossae. Para-aortic lymphadenectomy was only performed in case of positive palpation. Patients with deep myometrial invasion (1 50%) or undifferentiated tumors (G3) were treated with postoperative brachytherapy to the vaginal vault. Eight patients received external beam irradiation, 11 patients adjuvant hormonal therapy (TAM, MPA), none chemotherapy. Staging was performed according to the FIGO classification of 1988. Anamnestic information included age, family history of gynecological or breast cancer (at least 1 case), previous history of cancer or preceding lesions, and history of hormonal therapy (oral contraceptives, hormone replacement therapy). Patients were followed clinically for up to 186 months (median 98 months). Recurrences were histologically confirmed. Death reports were available.
Histology and DNA Extraction. Formalin-fixed, paraffin-embedded blocks of tumor specimens and additional non-tumor tissue from 112 patients were analyzed. 93% of the tumors encompassed endometrioid adenocarcinomas of various types (papillary, secretory, ciliated cell, adenoacanthoma, adenosquamous), 7% were clear cell, serous or mucinous carcinoma. In addition, 5 different myometrium samples randomly chosen from each year (1980-1994; total n = 90) served as controls to test the influence of fixatives, or fixation time on DNA quality. For tumor samples, hematoxylin-eosin staining was used for a repeated pathologic evaluation (e.g. TNM status, myometrial invasion, grading, histological typing, lymph node involvement). ER and PgR expression was determined and scored on newly prepared 5-Ìm sections by immunohistochemistry [25] . The amount of tumor cells in sections of endometrial carcinomas was estimated by visual examination of 5-Ìm HE-stained sections. Adjacent 40-Ìm toluidine-stained tumor sections with a high content of tumor cells (1 70%) were used for microdissection [26] . DNA was extracted from the tumor sections as previously described [27] .
Amplification of c-erbB2, c-myc and int-2 Gene. Differential PCR combined with fluorescent DNA technology was used for quantitative determination of c-erbB2, c-myc and int-2 oncogene amplification in tumor samples. PCR reactions, fragment analysis, and assessment of oncogene amplification were performed as previously reported [27, 28] . Briefly, the gene of interest and an unamplified reference gene (y-IFN) were amplified in a multiplex PCR using fluorescent-labelled primers. In each PCR experiment, DNA extracted from normal placenta as reference tissue with non-amplified target genes was included. PCR products were electrophoresed on an automated fluorescent DNA sequencer (A.L.F. TM Pharmacia, Freiburg, Germany). Fluorescent emission data collected during the electrophoresis were calculated using AlleleLinks TM software (Pharmacia). Amplification of target genes in tumor tissue, which reflects the ratio of the gene copy numbers of the oncogene and the y-IFN reference gene, was estimated from the ratio of peak areas using placenta DNA for normalization. Results of at least two independent assays were calculated with the equation: amplification n = (P t /P r )/(P t placenta /P r placenta ), where P t = peak area of target gene signal and P r = peak area of reference gene signal (y-IFN).
Mutation of the K-ras Gene. Mutation of the K-ras gene at codons 12/13 and 61 were examined by PCR-SSCP and direct sequencing. Exon 1 and 2 of the K-ras gene were amplified by PCR using the following primer pairs: for codon 12/13, 5)-CATGTTCTAATA-TAGTCACA-3) (forward) and 5)-GTTATCTCCATTTAGAACAA-3) (reverse); for codon 61, 5)-TTCCTACAGGAAGCAAGTAG-3) (forward) and 5)-GATGAACGAAGGACATCCTT-3) (reverse). PCR was performed in 50 Ìl with 2 Ìl of genomic DNA isolated from paraffin sections, 40 pmol of each primer, 20 mM Tris-HCl (pH 8.4), 50 mM KCl, 1.5 mM MgCl 2 , 200 ÌM of each dNTP and 2.0 units of Taq polymerase (Pharmacia). An initial denaturation of 10 min at 94°C was followed by 35 cycles of 1 min at 94°C, 1 min at 49°C for codon 12/13 or at 55°C for codon 61 and 1 min at 72°C, and a final elongation step (8 min at 72°C). PCR products were screened for mutations by the SSCP method on 6% polyacrylamide gels run at 5 W at 10°C and visualized by silver staining as described [29] . For sequencing, PCR products were purified with the MicroSpin Columns (Pharmacia). Both strands of DNA were sequenced by the dideoxy method using Thermo-Sequenase according to the manufacturer's protocol (Amersham Life Science, Slough, UK).
Statistical Methods. Associations of c-erbB2 amplification and Kras mutation with other clinicopathological factors were calculated by ¯2 test. Probabilities of relapse-free survival and overall survival (OS) were calculated using the method of Kaplan-Meier, statistical differences were evaluated by log-rank test.
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Results
In DNA extracted from sections of a total of 112 primary endometrial cancers with reference tissue from the same patients and in 90 benign, randomly chosen myometrium samples, amplification of c-erbB2, c-myc and int-2 was analyzed using fluorescent differential PCR ( fig. 1 ). c-erbB2 gene amplification (2-to 10-fold) was observed in 21(18.6%) of the 112 endometrial carcinomas examined. Amplification of c-myc and int-2 genes was found in 3 (2.7%, 3-to 4-fold) and 5 (4.4%, 2-to 5-fold) tumors, respectively (table 1). No amplification of the three oncogenes could be detected in any of the benign reference and additional myometrium samples analyzed.
All cases were screened for mutations at codon 12/13 and codon 61 of the K-ras oncogene by PCR-SSCP analysis and direct double-stranded DNA sequencing. K-ras mutations were observed in 13 (11.5%) of 112 carcinomas, 10 mutations were found in codon 12, and 3 in codon 61 (table 1, fig. 2 ).
Due to the low number of c-myc and int-2 amplification, no associations between amplification of these genes and clinical factors were analyzed. Associations between cerbB2 gene amplification and K-ras mutation and patient age and pathohistological factors were determined (table 2). No significant associations between c-erbB2 gene shows a heterozygous point mutation at codon 12 (GGT to GAT, Gly to ASP), T2 shows a homozygous point mutation at codon 61 (CAA to CAC, Gln to His). amplification and any clinical factor were observed. K-ras gene mutation correlated significantly with higher PgR expression (p ! 0.05), but with none of the other clinical parameters and survival of the patients (table 2) . For disease-free survival (DFS) and overall survival (OS) clinical parameters including PgR expression revealed significant prognostic value. For c-erbB2 amplification and K-ras mutation no prognostic information was achieved (table 3) .
Discussion
The systemic management of endometrial cancer patients is mainly based on histopathological criteria such as myometrial invasion, tumor grading, and extrauterine Niederacher/An/Cho/Hantschmann/ Bender/Beckmann tumor spread. However, these parameters are evidently unable to sufficiently characterize the biological behavior of endometrium cancer [1, 2] . Analyses of genetic alterations are relevant for the understanding of tumor genetics and may provide prognostic information for the individual patient [15, 30] . The role of oncogene activation in endometrial cancer is incompletely characterized. Most of the studies published on oncogene amplification in endometrial cancer only examined small numbers of cases, often with conflicting results [10] [11] [12] [31] [32] [33] . In this study, amplification of c-erbB2, c-myc, and int-2 were determined in 112 endometrial cancers. To date, this is the largest study performed on endometrial cancer bearing oncogene amplification with differential PCR. Amplification of c-erbB2, c-myc and int-2 were found in 18.6, 2.7 and 4.4% of endometrial cancers analyzed. The detected rates of oncogene amplification are in agreement with previous studies [10] [11] [12] [31] [32] [33] .
Amplification of c-myc or int-2 is very low, implicating a subordinate role of these oncogenes in the development of sporadic endometrial cancer. Numerous studies have demonstrated that amplification and overexpression of cerbB2 in endometrial cancer correlated with clinical and pathohistological factors such as histological grade. Furthermore, it was suggested that c-erbB2 is of prognostic value [10-12, 31, 32] . In contrast to these findings, we could not demonstrate any significant correlation between the amplification of the c-erbB2 gene and clinical factors, as well as the DFS and OS of the patients. These results have been supported by Monk et al. [33] . Sample size, tumor histology or technical variations may account for this discrepancy. Further studies in strictly defined populations with standard analytical techniques may have to clarify the prognostic significance of c-erbB2 amplification in endometrial cancer.
A rare genetic phenomenon is the mutation of an oncogene. Mutations in the K-ras oncogene occur in 10-50% of several tumor types including endometrial cancer [16] [17] [18] . K-ras mutations also have been found in endometrial hyperplasia, suggesting that activation of K-ras represents an early event in the development of endometrial cancer [16] . In this study, K-ras mutations could be detected in 11.5% of endometrial cancers. There were no correlations between K-ras point mutation and clinical stage, histological grade and clinical outcome of the patients, in agreement with other studies [16] [17] [18] 34] . Mutations of the ras oncogene alter the ras product by abolishing their intrinsic GTPase activity, which results in autonomous cell growth [35] . Activation of the guanine nucleotide binding protein ras enhance estrogen-induced and antiestrogen (tamoxifen)-induced transcriptional activity of the ER activation function 1 [36, 37] . These findings are in agreement with the results of this study. A significant correlation was found between ER-dependent PgR expression and activating K-ras mutations. This suggests that enhanced activity of the ER activation function 1 by stimulating phosphorylation mediated through mutational activation of the ras-MAPK cascade may be one mechanism of hormone independence of endometrial cancer. This may contribute to the development of (anti-)hormone resistance of steroid-receptor-positive endometrial cancer.
